Poultry red mite (PRM), also known as
Dermanyssus gallinae, poses a significant threat to poultry farms, particularly laying pullets, as it is an obligatory blood feeder. This exoparasite not only affects the welfare and productivity of both traditional and industrial poultry farms but also poses concerns for human health in residential areas, potentially irritating farm workers (
1-
12). Recent studies highlight a concerning increase in PRM incidence in Europe, with average rates reaching 83% among layers and peaking at 92% in countries like the Netherlands, Germany, and Belgium (
6,
9). PRM incidence has been observed across all types of poultry flocks, including organic, layers, poultry meat, traditional, and backyard chickens (
6). The rising concerns surrounding PRM have complicated its treatment, with conventional methods relying on miticides such as carbamates, organophosphates, amidines, pyrethroids, and more recently, spinosad in powder, mist, and spray forms (
13-
15). However, these conventional approaches face limitations such as difficulty in administering effective doses across all infested areas, causing additional stress to flocks, drug residue in birds and humans, and the emergence of miticide resistance (
1,
13-
18).
Fluralaner, an isoxazoline compound, is utilized as a systemic treatment for PRM. It functions as a potent inhibitor of the arthropod nervous system by antagonizing ligand-gated chloride channels (GABA-receptor and glutamate-receptor), which are abundant in the central and peripheral muscle-nervous systems of mites (
19-
21). This mechanism sets it apart from other miticides. Studies by Heckeroth et al. administered two doses of 0.5 mg/kg of Fluralaner with a one-week interval, resulting in an average reduction of the mite population by 99% fifteen days after the first administration (
22). Additionally, Prohaczik et al. safely administered Fluralaner at a dose of 2.5 mg/kg repeatedly, further validating its efficacy (
23). Following trials and the assessment of drug residue, Fluralaner received authorization for PRM treatment (
24).